Akcea Therapeutics, Inc. Operating Expenses
Akcea Therapeutics, Inc. reported Operating Expenses of $82.25 million for the 3-month period ending 2018-12-31, per its 10-K filed 2019-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2019-03-01
- Akcea Therapeutics, Inc. operating expenses for the quarter ending 2018-12-31 was $82.25M, a 91.35% increase year-over-year.
- Akcea Therapeutics, Inc. operating expenses for the quarter ending 2018-09-30 was $84.25M, a 223.87% increase year-over-year.
- Akcea Therapeutics, Inc. operating expenses for the quarter ending 2018-06-30 was $81.74M, a 221.80% increase year-over-year.
- Akcea Therapeutics, Inc. operating expenses for the quarter ending 2018-03-31 was $47.44M, a 31.72% decline year-over-year.
- Akcea Therapeutics, Inc. operating expenses for fiscal 2018 was $295.68M, a 80.44% increase from fiscal 2017.
- Akcea Therapeutics, Inc. operating expenses for fiscal 2017 was $163.87M, a 96.22% increase from fiscal 2016.
- Akcea Therapeutics, Inc. operating expenses for fiscal 2016 was $83.51M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2018-12-31 | $82.25M 10-K · filed 2019-03-01 | $166.50M derived: sum of 2 quarters · filed 2019-03-01 | $248.25M derived: sum of 3 quarters · filed 2019-03-01 | $295.68M 10-K · filed 2019-03-01 |
| 2018-09-30 | $84.25M 10-K · filed 2019-03-01 | $165.99M derived: sum of 2 quarters · filed 2019-03-01 | $213.43M 10-Q · filed 2018-11-06 | $256.41M derived: sum of 4 quarters · filed 2019-03-01 |
| 2018-06-30 | $81.74M 10-K · filed 2019-03-01 | $129.18M 10-Q · filed 2018-08-07 | $172.16M derived: sum of 3 quarters · filed 2019-03-01 | $198.18M derived: sum of 4 quarters · filed 2019-03-01 |
| 2018-03-31 | $47.44M 10-K · filed 2019-03-01 | $90.42M derived: sum of 2 quarters · filed 2019-03-01 | $116.43M derived: sum of 3 quarters · filed 2019-03-01 | $141.84M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-12-31 | $42.99M 10-K · filed 2019-03-01 | $69.00M derived: sum of 2 quarters · filed 2019-03-01 | $94.40M derived: sum of 3 quarters · filed 2019-03-01 | $163.87M 10-K · filed 2019-03-01 |
| 2017-09-30 | $26.01M 10-K · filed 2019-03-01 | $51.41M derived: sum of 2 quarters · filed 2019-03-01 | $120.88M 10-Q · filed 2018-11-06 | $154.74M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $25.40M 10-K · filed 2019-03-01 | $94.87M 10-Q · filed 2018-08-07 | $128.73M derived: sum of 3 quarters · filed 2019-03-01 | $148.63M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $69.47M 10-K · filed 2019-03-01 | $103.33M derived: sum of 2 quarters · filed 2019-03-01 | $123.23M derived: sum of 3 quarters · filed 2019-03-01 | $136.93M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $33.85M 8-K · filed 2018-09-18 | $53.76M derived: sum of 2 quarters · filed 2018-09-18 | $67.46M derived: sum of 3 quarters · filed 2018-09-18 | $83.51M 10-K · filed 2019-03-01 |
| 2016-09-30 | $19.90M 8-K · filed 2018-09-18 | $33.61M derived: sum of 2 quarters · filed 2018-09-18 | $49.65M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $13.71M 8-K · filed 2018-09-18 | $29.75M 10-Q · filed 2017-08-09 | ||
| 2016-03-31 | $16.05M 8-K · filed 2018-09-18 | |||
| 2015-12-31 | $61.44M 8-K · filed 2018-09-18 |